The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.
Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.
Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.
Jamile M. Shammo, MD, discusses how the differences between the available JAK inhibitors in myelofibrosis guide her treatment considerations.
Satya (Nanu) Das, MD, MSCI, pens this piece on what a career in drug development in the biopharmaceutical field may look like.
Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.
Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.
Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.
Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared…
A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.
